Jan M. Lundberg

Jan M. Lundberg appears at Eli Lilly & Co under the title EVP,Science&Tech and Pres. LRL (9 filings) and at Ardelyx, Inc. as a Director (6). The 15 filings in the record, published from January 28, 2016 to June 16, 2023, are all pay in shares: 12 share grants and 3 option exercises. No purchase or sale is recorded.

The years 2016, 2017 and 2018 are the fullest, with 3, 3 and 4 filings; the years 2019 to 2023 have just one each. The record thus loses volume from 2019, with one line a year up to the last, published June 16, 2023.

The median publication delay is 2 days, across 15 dated filings. No filing falls in the past year, and the record links no colleague at Eli Lilly or Ardelyx to nearby trades, so the grants of Jan M. Lundberg read on their own, with nothing to set beside them.